Ocular Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Ocular Therapeutix
OCUL Stock  USD 10.89  0.62  6.04%   
Ocular Therapeutix's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Ocular Therapeutix's valuation are provided below:
Gross Profit
-137.7 M
Market Capitalization
2.2 B
Enterprise Value Revenue
34.4233
Revenue
55.8 M
Earnings Share
(1.43)
There are over one hundred nineteen available trending fundamental ratios for Ocular Therapeutix, which can be analyzed over time and compared to other ratios. We recommend to check out Ocular Therapeutix's recent fundamental drivers against the all of the trends between 2010 and 2026. Market Cap is expected to rise to about 1.3 B this year. Enterprise Value is expected to rise to about 978.3 M this year

Ocular Therapeutix Total Revenue

76.95 Million

Check Ocular Therapeutix financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ocular Therapeutix's main balance sheet or income statement drivers, such as Depreciation And Amortization of 4.6 M, Interest Expense of 16.4 M or Selling General Administrative of 73.2 M, as well as many indicators such as Price To Sales Ratio of 23.17, Dividend Yield of 0.0 or PTB Ratio of 4.05. Ocular financial statements analysis is a perfect complement when working with Ocular Therapeutix Valuation or Volatility modules.
  
Build AI portfolio with Ocular Stock
Check out the analysis of Ocular Therapeutix Correlation against competitors.
For more information on how to buy Ocular Stock please use our How to buy in Ocular Stock guide.

Ocular Therapeutix Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets553 M526.6 M174.8 M
Slightly volatile
Short and Long Term Debt Total91.5 M87.2 M40.1 M
Slightly volatile
Other Current Liabilities42.4 M40.4 M14 M
Slightly volatile
Total Current Liabilities49.9 M47.6 M19.2 M
Slightly volatile
Other Liabilities18.3 M22.8 M15.6 M
Slightly volatile
Property Plant And Equipment Net10.5 M17.6 M9.1 M
Slightly volatile
Accounts Payable3.2 M4.8 M2.7 M
Slightly volatile
Cash473.5 M450.9 M138.1 M
Slightly volatile
Non Current Assets Total12.3 M19.5 M10.6 M
Slightly volatile
Non Currrent Assets Other1.8 M1.9 M1.5 M
Slightly volatile
Other Assets1.091.151.4 M
Very volatile
Long Term Debt82.7 M78.8 M34.6 M
Slightly volatile
Cash And Short Term Investments473.5 M450.9 M146.7 M
Slightly volatile
Net Receivables39.1 M37.2 M11.4 M
Slightly volatile
Common Stock Shares Outstanding191.1 M182 M60.3 M
Slightly volatile
Liabilities And Stockholders Equity553 M526.6 M174.8 M
Slightly volatile
Non Current Liabilities Total72.8 M116.4 M69.8 M
Slightly volatile
Other Current Assets16.2 M15.5 M4.8 M
Slightly volatile
Total Liabilities91.6 M164 M87.2 M
Slightly volatile
Property Plant And Equipment Gross47.1 M44.8 M15.4 M
Slightly volatile
Total Current Assets532.5 M507.1 M163.7 M
Slightly volatile
Short Term Debt3 M1.7 M3.2 M
Very volatile
Property Plant Equipment7.1 M11.3 M6.5 M
Slightly volatile
Current Deferred Revenue139.8 K147.2 K4.4 M
Very volatile
Common Stock Total Equity5.3 K9.2 K4.8 K
Slightly volatile
Long Term Debt Total33.7 M62.1 M31.4 M
Slightly volatile
Capital Surpluse424.2 M750 M384.8 M
Slightly volatile
Inventory3.7 M3.5 M1.1 M
Slightly volatile
Deferred Long Term Liabilities6.9 M7.3 M10.1 M
Pretty Stable
Short and Long Term Debt7 M9.5 M6.1 M
Slightly volatile
Net Invested Capital463.5 M441.4 M133.5 M
Slightly volatile
Net Working Capital482.6 M459.6 M138.6 M
Slightly volatile
Capital Stock9.6 K18.4 K7.1 K
Slightly volatile
Capital Lease Obligations7 M6.6 M9.2 M
Slightly volatile

Ocular Therapeutix Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization4.6 M4.4 M2 M
Slightly volatile
Interest Expense16.4 M15.6 M5.5 M
Slightly volatile
Selling General Administrative73.2 M69.8 M26.5 M
Slightly volatile
Selling And Marketing Expenses50.2 M47.8 M18.1 M
Slightly volatile
Total Revenue76.9 M73.3 M23.4 M
Slightly volatile
Other Operating Expenses284.4 M270.8 M96.8 M
Slightly volatile
Research Development154.1 M146.8 M49.9 M
Slightly volatile
Cost Of Revenue6.8 M6.5 M2.9 M
Slightly volatile
Total Operating Expenses277.6 M264.4 M94.5 M
Slightly volatile
Preferred Stock And Other Adjustments8.8 K9.9 K10.8 K
Slightly volatile
Interest Income24.5 M23.3 M5 M
Slightly volatile
Reconciled Depreciation2.8 M4.4 M2.3 M
Slightly volatile

Ocular Therapeutix Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation40 M38.1 M12.1 M
Slightly volatile
Begin Period Cash Flow238.6 M227.2 M87.2 M
Slightly volatile
Depreciation4.6 M4.4 M2 M
Slightly volatile
Capital Expenditures2.6 M1.5 M2.1 M
Slightly volatile
Total Cash From Financing Activities401 M381.9 M113.4 M
Slightly volatile
End Period Cash Flow475.4 M452.8 M139.3 M
Slightly volatile
Sale Purchase Of Stock698 K1.2 M535.4 K
Slightly volatile
Change To Liabilities1.7 M1.2 M1.2 M
Slightly volatile
Issuance Of Capital Stock382 M363.8 M111.6 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio23.1724.39758
Slightly volatile
Days Sales Outstanding286213415
Slightly volatile
Stock Based Compensation To Revenue0.570.65.7822
Slightly volatile
Capex To Depreciation0.370.391.2819
Pretty Stable
EV To Sales17.7518.68401
Slightly volatile
Inventory Turnover2.712.132.0346
Slightly volatile
Days Of Inventory On Hand203227270
Slightly volatile
Payables Turnover2.191.551.7457
Pretty Stable
Sales General And Administrative To Revenue1.041.0929.5203
Slightly volatile
Research And Ddevelopement To Revenue2.192.312.2079
Slightly volatile
Capex To Revenue0.02210.02324.252
Slightly volatile
Cash Per Share3.762.853.9583
Slightly volatile
Days Payables Outstanding2963126.4 K
Slightly volatile
Income Quality1.190.631.3553
Pretty Stable
Current Ratio8.9712.268.3034
Very volatile
Receivables Turnover4.522.263.4657
Very volatile
Capex Per Share0.00890.00940.0691
Slightly volatile
Revenue Per Share0.210.360.2206
Slightly volatile
Interest Debt Per Share1.090.651.0358
Slightly volatile
Debt To Assets0.220.150.2573
Pretty Stable
Operating Cycle472440590
Slightly volatile
Days Of Payables Outstanding2963126.4 K
Slightly volatile
Ebt Per Ebit1.171.31.0788
Very volatile
Quick Ratio8.9312.188.2688
Very volatile
Net Income Per E B T0.770.870.9452
Slightly volatile
Cash Ratio4.618.535.9817
Very volatile
Days Of Inventory Outstanding203227270
Slightly volatile
Days Of Sales Outstanding286213415
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.161.00961.0584
Slightly volatile
Fixed Asset Turnover3.933.741.5006
Slightly volatile
Debt Ratio0.220.150.2573
Pretty Stable
Price Sales Ratio23.1724.39758
Slightly volatile
Asset Turnover0.07740.130.0812
Slightly volatile
Gross Profit Margin0.620.820.7164
Slightly volatile

Ocular Therapeutix Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.3 B1.2 B441 M
Slightly volatile
Enterprise Value978.3 M931.7 M352.6 M
Slightly volatile

Ocular Fundamental Market Drivers

Ocular Upcoming Events

4th of March 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Ocular Therapeutix Financial Statements

Ocular Therapeutix investors utilize fundamental indicators, such as revenue or net income, to predict how Ocular Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue147.2 K139.8 K
Total Revenue73.3 M76.9 M
Cost Of Revenue6.5 M6.8 M
Stock Based Compensation To Revenue 0.60  0.57 
Sales General And Administrative To Revenue 1.09  1.04 
Research And Ddevelopement To Revenue 2.30  2.19 
Capex To Revenue 0.02  0.02 
Revenue Per Share 0.36  0.21 
Ebit Per Revenue(2.43)(2.55)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Ocular Therapeutix is a strong investment it is important to analyze Ocular Therapeutix's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ocular Therapeutix's future performance. For an informed investment choice regarding Ocular Stock, refer to the following important reports:
How To Invest In Ocular
Details
Is Ocular Stock a good investment?
Details
What is Ocular Therapeutix's Net Worth?
Details
Largest Pharmaceuticals Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Ocular Therapeutix Correlation against competitors.
For more information on how to buy Ocular Stock please use our How to buy in Ocular Stock guide.
You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ocular Therapeutix. If investors know Ocular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ocular Therapeutix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.43)
Revenue Per Share
0.321
Quarterly Revenue Growth
(0.06)
Return On Assets
(0.37)
Return On Equity
(0.82)
The market value of Ocular Therapeutix is measured differently than its book value, which is the value of Ocular that is recorded on the company's balance sheet. Investors also form their own opinion of Ocular Therapeutix's value that differs from its market value or its book value, called intrinsic value, which is Ocular Therapeutix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ocular Therapeutix's market value can be influenced by many factors that don't directly affect Ocular Therapeutix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Ocular Therapeutix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ocular Therapeutix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ocular Therapeutix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY